European and North American cohorts including over 40, 000 patients demonstrated that starting treatment earlier reduced the risk of acquired immune deficiency syndrome (AIDS) or death with those starting before reaching CD4 350 cells/mm3 having the most benefit [41]. This evidence concerns the gene CD4 and AIDS.